108 related articles for article (PubMed ID: 24726642)
1. TLR9 agonist regulates angiogenesis and inhibits corneal neovascularization.
Wu J; Cui H; Dick AD; Liu L
Am J Pathol; 2014 Jun; 184(6):1900-10. PubMed ID: 24726642
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib inhibits inflammatory corneal lymphangiogenesis.
Detry B; Blacher S; Erpicum C; Paupert J; Maertens L; Maillard C; Munaut C; Sounni NE; Lambert V; Foidart JM; Rakic JM; Cataldo D; Noël A
Invest Ophthalmol Vis Sci; 2013 May; 54(5):3082-93. PubMed ID: 23580490
[TBL] [Abstract][Full Text] [Related]
3. CXCL12/CXCR4 axis regulates neovascularization and lymphangiogenesis in sutured corneas in mice.
Du LL; Liu P
Mol Med Rep; 2016 Jun; 13(6):4987-94. PubMed ID: 27121088
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation.
Hos D; Bock F; Dietrich T; Onderka J; Kruse FE; Thierauch KH; Cursiefen C
Invest Ophthalmol Vis Sci; 2008 May; 49(5):1836-42. PubMed ID: 18436817
[TBL] [Abstract][Full Text] [Related]
5. Regulation of angiogenesis, mural cell recruitment and adventitial macrophage behavior by Toll-like receptors.
Aplin AC; Ligresti G; Fogel E; Zorzi P; Smith K; Nicosia RF
Angiogenesis; 2014 Jan; 17(1):147-61. PubMed ID: 24091496
[TBL] [Abstract][Full Text] [Related]
6. TLR9 (Toll-Like Receptor 9) Agonist Suppresses Angiogenesis by Differentially Regulating VEGFA (Vascular Endothelial Growth Factor A) and sFLT1 (Soluble Vascular Endothelial Growth Factor Receptor 1) in Preeclampsia.
He B; Yang X; Li Y; Huang D; Xu X; Yang W; Dai Y; Zhang H; Chen Z; Cheng W
Hypertension; 2018 Apr; 71(4):671-680. PubMed ID: 29437897
[TBL] [Abstract][Full Text] [Related]
7. The effect of podoplanin inhibition on lymphangiogenesis under pathological conditions.
Maruyama Y; Maruyama K; Kato Y; Kajiya K; Moritoh S; Yamamoto K; Matsumoto Y; Sawane M; Kerjaschki D; Nakazawa T; Kinoshita S
Invest Ophthalmol Vis Sci; 2014 Jul; 55(8):4813-22. PubMed ID: 24985477
[TBL] [Abstract][Full Text] [Related]
8. Serum eyedrops antagonize the anti(lymph)angiogenic effects of bevacizumab in vitro and in vivo.
Hos D; Koch KR; Bucher F; Bock F; Cursiefen C; Heindl LM
Invest Ophthalmol Vis Sci; 2013 Sep; 54(9):6133-42. PubMed ID: 23970469
[TBL] [Abstract][Full Text] [Related]
9. A Novel Peptide Derived From Tissue-Type Plasminogen Activator Potently Inhibits Angiogenesis and Corneal Neovascularization.
Kim HK; Choi JS; Lee SW; Joo CK; Joe YA
J Cell Biochem; 2017 May; 118(5):1132-1143. PubMed ID: 27618679
[TBL] [Abstract][Full Text] [Related]
10. Pleiotropic action of CpG-ODN on endothelium and macrophages attenuates angiogenesis through distinct pathways.
Wu J; Su W; Powner MB; Liu J; Copland DA; Fruttiger M; Madeddu P; Dick AD; Liu L
Sci Rep; 2016 Aug; 6():31873. PubMed ID: 27558877
[TBL] [Abstract][Full Text] [Related]
11. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves the antiangiogenic efficacy for advanced stage mouse corneal neovascularization.
Chaoran Z; Zhirong L; Gezhi X
Graefes Arch Clin Exp Ophthalmol; 2011 Oct; 249(10):1493-501. PubMed ID: 21574021
[TBL] [Abstract][Full Text] [Related]
12. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment.
Cursiefen C; Chen L; Borges LP; Jackson D; Cao J; Radziejewski C; D'Amore PA; Dana MR; Wiegand SJ; Streilein JW
J Clin Invest; 2004 Apr; 113(7):1040-50. PubMed ID: 15057311
[TBL] [Abstract][Full Text] [Related]
13. Platelet-activating factor (PAF) induces corneal neovascularization and upregulates VEGF expression in endothelial cells.
Ma X; Ottino P; Bazan HE; Bazan NG
Invest Ophthalmol Vis Sci; 2004 Sep; 45(9):2915-21. PubMed ID: 15326102
[TBL] [Abstract][Full Text] [Related]
14. Early effects of dexamethasone and anti-VEGF therapy in an inflammatory corneal neovascularization model.
Mirabelli P; Peebo BB; Xeroudaki M; Koulikovska M; Lagali N
Exp Eye Res; 2014 Aug; 125():118-27. PubMed ID: 24933712
[TBL] [Abstract][Full Text] [Related]
15. Topical Ranibizumab inhibits inflammatory corneal hem- and lymphangiogenesis.
Bucher F; Parthasarathy A; Bergua A; Onderka J; Regenfuss B; Cursiefen C; Bock F
Acta Ophthalmol; 2014 Mar; 92(2):143-8. PubMed ID: 22994268
[TBL] [Abstract][Full Text] [Related]
16. Activation of CD36 inhibits and induces regression of inflammatory corneal neovascularization.
Mwaikambo BR; Sennlaub F; Ong H; Chemtob S; Hardy P
Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4356-64. PubMed ID: 17003426
[TBL] [Abstract][Full Text] [Related]
17. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.
Cheng N; Brantley DM; Liu H; Lin Q; Enriquez M; Gale N; Yancopoulos G; Cerretti DP; Daniel TO; Chen J
Mol Cancer Res; 2002 Nov; 1(1):2-11. PubMed ID: 12496364
[TBL] [Abstract][Full Text] [Related]
18. Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation.
Bachmann BO; Bock F; Wiegand SJ; Maruyama K; Dana MR; Kruse FE; Luetjen-Drecoll E; Cursiefen C
Arch Ophthalmol; 2008 Jan; 126(1):71-7. PubMed ID: 18195221
[TBL] [Abstract][Full Text] [Related]
19. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas.
Philipp W; Speicher L; Humpel C
Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2514-22. PubMed ID: 10937562
[TBL] [Abstract][Full Text] [Related]
20. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
